<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22502" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Halobetasol Cream</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awad</surname>
            <given-names>Nardin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nardin Awad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22502.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Halobetasol cream is a medication used in the management and treatment of psoriasis. It is in the topical corticosteroid class of drugs. This activity outlines the indications, action, and contraindications for halobetasol as a valuable agent in managing psoriasis (and other disorders when applicable). This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to interprofessional team members in the care of patients with psoriasis and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanism of action of halobetasol cream.</p></list-item><list-item><p>Describe the possible adverse effects of halobetasol cream.</p></list-item><list-item><p>Outline the appropriate indications for using halobetasol cream.</p></list-item><list-item><p>Explain some interprofessional team strategies for improving care coordination and communication to advance halobetasol cream and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22502&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22502">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22502.s2" sec-type="Indications">
        <title>Indications</title>
        <p>As an ultra-high potency steroid, halobetasol cream has indications and FDA approval for use in the treatment of many inflammatory and pruritic dermatological conditions. It is typically used for the treatment of plaque psoriasis but also has indications for use in several other dermatological conditions. A few common conditions include&#x000a0;atopic dermatitis, alopecia areata, cutaneous lichen planus, lichen simplex chronicus, and granuloma annularae.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref>&#x000a0;Under the US classification system, it is classified as a class I corticosteroid (i.e., highest potency class).<xref ref-type="bibr" rid="article-22502.r2">[2]</xref></p>
      </sec>
      <sec id="article-22502.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Although additional studies regarding the mechanism of action of topical corticosteroids are still necessary, topical corticosteroids, including halobetasol cream, generally have the same mechanism of action to exert their anti-inflammatory, immunosuppressive and anti-mitogenic effects.&#x000a0;Corticosteroids alter&#x000a0;the behavior of epidermal cells, dermal cells, and leukocytes that take part in skin diseases that are proliferative and inflammatory.<xref ref-type="bibr" rid="article-22502.r3">[3]</xref></p>
        <p>Corticosteroids&#x000a0;bind to glucocorticoid receptor proteins in the cytoplasm of a cell to form a steroid-receptor complex. In the unbound state, the receptor is cytoplasmic, but in the bound state, the complex moves into the cell nucleus and binds to DNA, changing mRNA transcription. Through this modification, corticosteroids can either increase or decrease the synthesis of proteins involved in the inflammation cascade and the immune response. Corticosteroids increase the&#x000a0;synthesis of lipocortin, which&#x000a0;acts to reduce&#x000a0;the activity of phospholipase A2, which releases arachidonic acid from phospholipids and thus decreases the synthesis of prostaglandins. Corticosteroids also&#x000a0;suppress&#x000a0;mRNA responsible for interleukin-1 formation. Together, these actions produce anti-inflammatory, immunosuppressive, and anti-mitogenic effects.<xref ref-type="bibr" rid="article-22502.r3">[3]</xref><xref ref-type="bibr" rid="article-22502.r4">[4]</xref></p>
      </sec>
      <sec id="article-22502.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Halobetasol cream is administered topically to the skin. As a cream, it is not occlusive like ointments, making it useful in intertriginous areas where ointments are inappropriate. Creams also vanish into the skin easily, making them cosmetically appealing to patients.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref> However, halobetasol propionate comes in a variety of different vehicles, including foams, lotions, and ointments. Foams are the least occlusive and spread rapidly, particularly in hairy areas, but they are generally expensive, whereas the&#x000a0;occlusive nature of ointments makes them better suited for thicker, hairless skin.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref></p>
        <p>The standard dosing of halobetasol cream is once to twice daily for two weeks.<xref ref-type="bibr" rid="article-22502.r5">[5]</xref> The patient can calculate the amount of steroid that they should administer to an area through the use of the fingertip unit method. A fingertip unit is represented by the amount that will cover from the tip of the finger to the finger's first crease.&#x000a0;For example, one hand-sized area of skin calls for&#x000a0;0.5 fingertip units, which are equivalent to 0.25 grams of medication.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref></p>
        <p>Halobetasol is most commonly available in 0.05% ointment and cream, although as mentioned above, foams and other dose forms are also available. Dosing for steroid-responsive dermatoses is once or twice daily for up to two weeks, with a maximum dosage of 50 g per week. Pateints should be instructed not to apply the drug to their faces, axillae, or groins.&#x000a0;</p>
      </sec>
      <sec id="article-22502.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects of halobetasol cream include striae, purpura, rosacea, and acne,&#x000a0;with the most common adverse effect being atrophy.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref><xref ref-type="bibr" rid="article-22502.r1">[1]</xref> Less common effects include hypertrichosis, alteration in pigmentation, delayed wound healing, and exacerbation of skin infections.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref> The application of&#x000a0;very potent steroids can also induce deep-tissue tinea (fungal) infection known as a Majocchi granuloma.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref></p>
        <p>Systemic adverse effects are also possible, although they are far less prevalent than local adverse effects.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref> Possible systemic effects include hyperglycemia, adrenal insufficiency, Cushing syndrome, suppression of the hypothalamic-pituitary-adrenal axis, and even glaucoma if applied close to the eyes.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref> Children are at increased risk of systemic adverse effects due to their larger skin surface area relative to body weight. Systemic adverse effects usually result from misuse, such as applying topical corticosteroids to extensive areas, especially under occlusion or for a prolonged period.<xref ref-type="bibr" rid="article-22502.r7">[7]</xref></p>
      </sec>
      <sec id="article-22502.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The treatment of primary bacterial infections, such as impetigo, furuncles, carbuncles, ecthyma, and cellulitis by topical corticosteroids, is an absolute contraindication.&#x000a0;The steroid may mask the infection and make it much more difficult to accurately diagnose and treat.<xref ref-type="bibr" rid="article-22502.r8">[8]</xref> Relative contraindications for topical steroids use include candida and dermatophytes.&#x000a0;Topical steroids may be used as secondary treatments to decrease inflammation and pruritis in these conditions when appropriate.<xref ref-type="bibr" rid="article-22502.r8">[8]</xref></p>
      </sec>
      <sec id="article-22502.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Halobetasol cream is typically used once or twice daily for two weeks in patients with plaque psoriasis.<xref ref-type="bibr" rid="article-22502.r9">[9]</xref><xref ref-type="bibr" rid="article-22502.r5">[5]</xref> As an ultra-high potency steroid, patients should not use halobetasol cream for more than three weeks continuously.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref>&#x000a0;The drug's high potency makes it more likely&#x000a0;to precipitate adverse effects&#x000a0;to occur with prolonged use, including, but not limited to, atrophy, striae, bruising, hypertrichosis, Cushing syndrome, and&#x000a0;suppression of the hypothalamic-pituitary-adrenal axis. Patients should not use ultra-high-potency steroids&#x000a0;like halobetasol cream on the face, groin, axilla, or under occlusion, as these areas have thinner skin, and&#x000a0;the intertriginous regions are more likely to develop such adverse effects.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref> Patients should be monitored&#x000a0;at follow-up visits every two to three weeks to reassess the condition being treated and modify the use of the corticosteroid cream, if necessary.<xref ref-type="bibr" rid="article-22502.r10">[10]</xref></p>
      </sec>
      <sec id="article-22502.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topical corticosteroids, including halobetasol cream, are commonly prescribed by dermatologists for the treatment and management of many inflammatory and pruritic conditions of the skin. They provide rapid relief to patients for a plethora of conditions, and therefore, prescriptions for these agents are very common. However, proper counseling by the physician and pharmacist is not always adequately provided to the patient. Misuse of steroids can lead to clinically serious systemic and/or local effects.<xref ref-type="bibr" rid="article-22502.r10">[10]</xref></p>
        <p>It is crucial to give patients the correct dosage form when prescribing topical corticosteroids. Solutions, foams, gels, lotions, creams, and ointments all have appropriate clinical applications. The proper frequency, amount, and duration of treatment should also be emphasized to patients to avoid overtreating an area, leading to adverse effects, or undertreating an area, leading to poor therapeutic outcomes.<xref ref-type="bibr" rid="article-22502.r10">[10]</xref> Intertriginous regions should not have treatment with ointments, for example, and very rarely should a topical steroid be applied to a particular area more than twice a day.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref></p>
        <p>Additionally, glucocorticoid potency is an essential pharmacologic factor to take into account. Sometimes it is better to prescribe a more potent&#x000a0;steroid to provide rapid control of the disease and stop treatment quickly, rather than use a less potent steroid for an extended period, especially in cases of&#x000a0;self-limited conditions&#x000a0;such as&#x000a0;acute irritant dermatitis, panderous dermatitis, etc.<xref ref-type="bibr" rid="article-22502.r10">[10]</xref> However, in other situations, using a less potent formulation (such as halobetasol 0.01% lotion) can offer the same results as a more potent formulation (halobetasol 0.05% cream),&#x000a0;in which case the less potent option should be the choice to decrease the possibility of overtreatment and adverse drug effects.<xref ref-type="bibr" rid="article-22502.r11">[11]</xref>&#x000a0;Generally, the least potent steroid should be used for the shortest time while still maintaining therapeutic effectiveness.<xref ref-type="bibr" rid="article-22502.r1">[1]</xref></p>
        <p>Additionally, patients may have&#x000a0;concerns about&#x000a0;prescribed topical steroids that lead to nonadherence due to fear of harming themselves. This factor leads to&#x000a0;a significant proportion of patients that do not receive adequate treatment. Therefore, patient education is also important to dispel fears and false notions and ensure the safe use of topical corticosteroids.<xref ref-type="bibr" rid="article-22502.r6">[6]</xref> Nursing and pharmacy can both offer patient counsel on proper administration and alert the patient of specific signs of toxicity to watch for so they can inform their prescriber promptly. The pharmacist should also check for potential interactions, verify that dosing is appropriate, and notify the prescriber of any concerns. These are but a few examples of interprofessional teamwork that can improve patient outcomes and minimize adverse events.</p>
        <p>Therapy with halobetasol requires an interprofessional team approach, including physicians, specialty-trained nurses, and pharmacists, collaborating across disciplines to achieve optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-22502.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22502&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22502">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22502/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22502">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22502.s10">
        <title>References</title>
        <ref id="article-22502.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ference</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Last</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Choosing topical corticosteroids.</article-title>
            <source>Am Fam Physician</source>
            <year>2009</year>
            <month>Jan</month>
            <day>15</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-40</page-range>
            <pub-id pub-id-type="pmid">19178066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balkrishnan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Class I topical corticosteroid use by psoriasis patients in an academic practice.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-8</page-range>
            <pub-id pub-id-type="pmid">15764038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kragballe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroids: mechanisms of action.</article-title>
            <source>Acta Derm Venereol Suppl (Stockh)</source>
            <year>1989</year>
            <volume>151</volume>
            <fpage>7</fpage>
            <page-range>7-10; discussion 47-52</page-range>
            <pub-id pub-id-type="pmid">2533778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Nadkarni</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Godse</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroids in dermatology.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-8</page-range>
            <pub-id pub-id-type="pmid">27279294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Buxman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prawer</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Schwartzel</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6 Pt 2</issue>
            <fpage>1175</fpage>
            <page-range>1175-8</page-range>
            <pub-id pub-id-type="pmid">1757613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengge</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cork</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of topical glucocorticosteroids.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15; quiz 16-8</page-range>
            <pub-id pub-id-type="pmid">16384751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yawalkar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6 Pt 2</issue>
            <fpage>1166</fpage>
            <page-range>1166-9</page-range>
            <pub-id pub-id-type="pmid">1757611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornell</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Contraindications for using topical steroids.</article-title>
            <source>West J Med</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>147</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-60</page-range>
            <pub-id pub-id-type="pmid">18750337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kerdel</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Cook-Bolden</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Bagel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Israel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramakrishna</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1062</fpage>
            <page-range>1062-1069</page-range>
            <pub-id pub-id-type="pmid">30365586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saraswat</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ethical use of topical corticosteroids.</article-title>
            <source>Indian J Dermatol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>469</fpage>
            <page-range>469-72</page-range>
            <pub-id pub-id-type="pmid">25284852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22502.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerdel</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Draelos</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-339</page-range>
            <pub-id pub-id-type="pmid">30207807</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
